Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.76 |
| ▸ | ABL1 | P00519 | 6/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.76 |
| ▸ | SRC | P12931 | 6/20 | 0.76 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.76 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.71 |
| ▸ | BUB1 | O43683 | 1/20 | 0.71 |
| ▸ | STK10 | O94804 | 1/20 | 0.71 |
| ▸ | CARS1 | P49589 | 1/20 | 0.71 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.71 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.71 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797080 | 0.96 | EGFR (0.81) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL5843315 | 0.87 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL19314794 | 0.87 | EGFR (0.76) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL5842496 | 0.87 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL5843277 | 0.87 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL5842785 | 0.87 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL12610821 | 0.86 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB | |
| Icotinib SCHEMBL29355667 | 0.84 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB | |
| Icotinib SCHEMBL29544144 | 0.84 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB | |
| SCHEMBL18700323 | 0.84 | EGFR (0.71) | EGFRABL1FGFR1SRCPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-4119552-A1 | REGULATING CHIMERIC ANTIGEN RECEPTORS | Dana-Farber Cancer Institute, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| US-11311609-B2 | Regulating chimeric antigen receptors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | EGFR 278/4885ABL1 1463/4885FGFR1 2573/4885 |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | EGFR 793/4885ABL1 3456/4885FGFR1 2612/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | EGFR 793/4885ABL1 3456/4885FGFR1 2612/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | EGFR 1571/4885ABL1 2538/4885FGFR1 3358/4885 |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | EGFR 278/4885ABL1 1463/4885FGFR1 2573/4885 |
| US-11311609-B2 | Regulating chimeric antigen receptors | NFATC1, TNFRSF9, IL2RA | EGFR 659/4885ABL1 2453/4885FGFR1 1542/4885 |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | EGFR 674/4885ABL1 2466/4885FGFR1 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.